

Emilio Alba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4006547/publications.pdf>

Version: 2024-02-01

232
papers

8,942
citations

43973

48
h-index

49773

87
g-index

239
all docs

239
docs citations

239
times ranked

11436
citing authors

#	ARTICLE	IF	CITATIONS
1	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	13.9	1,390
2	Missing data imputation using statistical and machine learning methods in a real breast cancer problem. <i>Artificial Intelligence in Medicine</i> , 2010, 50, 105-115.	3.8	381
3	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	13.9	363
4	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. <i>BMC Medical Genomics</i> , 2012, 5, 44.	0.7	250
5	Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 805-814.	3.0	208
6	A combined neural network and decision trees model for prognosis of breast cancer relapse. <i>Artificial Intelligence in Medicine</i> , 2003, 27, 45-63.	3.8	184
7	Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. <i>British Journal of Cancer</i> , 2002, 86, 1367-1372.	2.9	180
8	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. <i>Annals of Oncology</i> , 2015, 26, 1280-1291.	0.6	177
9	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210.	13.9	169
10	Seeing Topological Order in Time-of-Flight Measurements. <i>Physical Review Letters</i> , 2011, 107, 235301.	2.9	163
11	Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. <i>Annals of Oncology</i> , 2012, 23, 3069-3074.	0.6	158
12	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
13	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2018, 9, 26406-26416.	0.8	136
14	GLIM Criteria Using Hand Grip Strength Adequately Predict Six-Month Mortality in Cancer Inpatients. <i>Nutrients</i> , 2019, 11, 2043.	1.7	134
15	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2~ breast cancer patients: results from the GEICAM 9906 trial. <i>Breast Cancer Research</i> , 2014, 16, R38.	2.2	133
16	A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 487-493.	1.1	127
17	Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. <i>Oncologist</i> , 2009, 14, 1-11.	1.9	124
18	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1351-1360.	5.1	120

#	ARTICLE	IF	CITATIONS
19	Clinical Pattern and Therapeutic Results Achieved in 1490 Patients with Germ-Cell Tumours of the Testis: the Experience of the Spanish Germ-Cell Cancer Group (GG). <i>European Urology</i> , 2002, 42, 553-563.	0.9	115
20	Multicenter study evaluating a dual policy of postorchietomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. <i>Annals of Oncology</i> , 2003, 14, 867-872.	0.6	115
21	Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2587-2593.	0.8	115
22	A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 811-816.	3.2	113
23	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , 2012, 23, 625-631.	0.6	106
24	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 1532-1541.	2.9	100
25	Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. <i>Breast Cancer Research</i> , 2013, 15, R98.	2.2	91
26	Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment. <i>Cancers</i> , 2020, 12, 2465.	1.7	90
27	Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. <i>Annals of Oncology</i> , 2017, 28, 2943-2949.	0.6	89
28	Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer. <i>BioEssays</i> , 2007, 29, 1159-1168.	1.2	82
29	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013, 15, R105.	2.2	80
30	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. <i>Clinical Cancer Research</i> , 2016, 22, 560-566.	3.2	79
31	Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 149-157.	1.1	77
32	Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Oncology</i> , The, 2011, 12, 369-376.	5.1	73
33	A microRNA Signature Associated with Early Recurrence in Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e91884.	1.1	72
34	Epirubicinâ€“cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. <i>Annals of Oncology</i> , 2004, 15, 79-87.	0.6	69
35	Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 169-176.	1.1	69
36	Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclibâ€“+â€“letrozole: results from MONALEESA-2. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 535-545.	1.1	68

#	ARTICLE	IF	CITATIONS
37	Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. <i>Annals of Oncology</i> , 2004, 15, 1798-1804.	0.6	67
38	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 659-669.	1.1	64
39	A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression. <i>Current Drug Metabolism</i> , 2008, 9, 336-343.	0.7	61
40	Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic Trial. <i>Journal of Clinical Oncology</i> , 2000, 18, 2545-2552.	0.8	60
41	Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 583-586.	1.2	60
42	Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. <i>BMC Cancer</i> , 2010, 10, 136.	1.1	59
43	Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. <i>British Journal of Cancer</i> , 2014, 110, 1139-1147.	2.9	58
44	Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM). <i>Breast Cancer Research and Treatment</i> , 2007, 101, 215-223.	1.1	57
45	Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 265-272.	1.1	53
46	A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. <i>Radiotherapy and Oncology</i> , 2006, 79, 34-38.	0.3	52
47	Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1124.	1.3	52
48	Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer. <i>Oncology</i> , 2010, 79, 98-104.	0.9	50
49	New Insights into the Role of the Immune Microenvironment in Breast Carcinoma. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	50
50	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 286.	1.0	50
51	The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 293-299.	3.4	45
52	Challenges and achievements of liquid biopsy technologies employed in early breast cancer. <i>EBioMedicine</i> , 2020, 62, 103100.	2.7	44
53	Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). <i>Annals of Oncology</i> , 2010, 21, 195-198.	0.6	41
54	Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. <i>Oral Oncology</i> , 2013, 49, 182-185.	0.8	40

#	ARTICLE	IF	CITATIONS
55	Maintenance treatment in metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1907-1912.	1.1	39
56	First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 469-479.	1.1	39
57	Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 591-600.	1.1	38
58	Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1183.	1.0	38
59	Phase 1B/2 study of the HSP90 inhibitor ALY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. <i>Oncotarget</i> , 2016, 7, 37680-37692.	0.8	37
60	High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. <i>Oncologist</i> , 2016, 21, 150-155.	1.9	35
61	Negative Prognostic Impact of the Coexpression of Epidermal Growth Factor Receptor and c-erbB-2 in Locally Advanced Cervical Cancer. <i>Oncology</i> , 2009, 76, 133-141.	0.9	34
62	The Functional Interaction of 14-3-3 Proteins with the ERK1/2 Scaffold KSR1 Occurs in an Isoform-specific Manner. <i>Journal of Biological Chemistry</i> , 2008, 283, 17450-17462.	1.6	32
63	Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. <i>Clinical and Translational Oncology</i> , 2012, 14, 94-101.	1.2	32
64	18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1432-1441.	3.2	32
65	BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: The Spanish Germ-Cell Cancer Group experience (GC). <i>Annals of Oncology</i> , 1999, 10, 289-294.	0.6	31
66	Human pregnane X receptor is expressed in breast carcinomas, potential heterodimers formation between hPXR and RXR-alpha. <i>BMC Cancer</i> , 2008, 8, 174.	1.1	31
67	Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. <i>Psycho-Oncology</i> , 2018, 27, 1530-1537.	1.0	30
68	Elevated Serum Levels of Vascular Endothelial Growth Factor Are Associated With Tumor-Associated Macrophages in Primary Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2006, 125, 111-118.	0.4	29
69	Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study. <i>Cancers</i> , 2021, 13, 3215.	1.7	29
70	Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study.. <i>Journal of Clinical Oncology</i> , 1997, 15, 1118-1122.	0.8	28
71	Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. <i>BMC Cancer</i> , 2013, 13, 26.	1.1	28
72	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. <i>Clinical Cancer Research</i> , 2017, 23, 3035-3044.	3.2	28

#	ARTICLE	IF	CITATIONS
73	Predictive response factors (PRF) in an open, nonrandomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable HER2-negative breast cancer (BC).. Journal of Clinical Oncology, 2010, 28, 556-556.	0.8	26
74	Serum protein levels following surgery in breast cancer patients: A protein microarray approach. International Journal of Oncology, 2012, 41, 2200-2206.	1.4	25
75	The Role of Immunohistochemistry in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: An Old Tool With an Enduring Prognostic Value. Clinical Breast Cancer, 2013, 13, 146-152.	1.1	25
76	Shallow whole genome sequencing for robust copy number profiling of formalin-fixed paraffin-embedded breast cancers. Experimental and Molecular Pathology, 2018, 104, 161-169.	0.9	25
77	CT-Determined Sarcopenia in GLIM-Defined Malnutrition and Prediction of 6-Month Mortality in Cancer Inpatients. Nutrients, 2021, 13, 2647.	1.7	25
78	Anticipatory Nausea and Vomiting: Prevalence and Predictors in Chemotherapy Patients. Oncology, 1989, 46, 26-30.	0.9	24
79	Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clinical and Translational Oncology, 2011, 13, 426-429.	1.2	24
80	Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "cereal world" patients. Clinical and Translational Oncology, 2018, 20, 922-927.	1.2	22
81	Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. Critical Reviews in Oncology/Hematology, 2013, 85, 315-331.	2.0	21
82	Addressing critical issues in the development of an Oncology Information System. International Journal of Medical Informatics, 2013, 82, 398-407.	1.6	21
83	Outcomes of single versus double hormone receptor"positive breast cancer. A GEICAM/9906 sub-study. European Journal of Cancer, 2018, 94, 199-205.	1.3	21
84	Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer. Breast Cancer Research and Treatment, 2001, 66, 33-39.	1.1	19
85	Targeted treatment approaches in refractory germ cell tumors. Critical Reviews in Oncology/Hematology, 2019, 143, 130-138.	2.0	19
86	Follow-up of breast cancer stages I and II. An analysis of some common methods. European Journal of Cancer & Clinical Oncology, 1987, 23, 419-423.	0.9	18
87	Irinotecan-Induced Central Nervous System Toxicity: a Case Report. Journal of the National Cancer Institute, 1999, 91, 647-647.	3.0	18
88	Erythropoietin pharmacology. Clinical and Translational Oncology, 2007, 9, 715-722.	1.2	18
89	Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction. Seminars in Cancer Biology, 2022, 83, 584-595.	4.3	18
90	The role of CDK4/6 inhibitors in early breast cancer. Breast, 2021, 58, 160-169.	0.9	18

#	ARTICLE	IF	CITATIONS
91	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. <i>Modern Pathology</i> , 2018, 31, 299-306.	2.9	17
92	Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001 study. <i>Journal of Clinical Oncology</i> , 2007, 25, 1007-1007.	0.8	17
93	Validation of the 2001 St Gallen Risk Categories for Node-Negative Breast Cancer Using a Database From the Spanish Breast Cancer Research Group (GEICAM). <i>Journal of Clinical Oncology</i> , 2004, 22, 961-962.	0.8	16
94	Elevated Vascular Endothelial Growth Factor Pretreatment Levels Are Correlated with the Tumor Burden in Hodgkin Lymphoma and Continue to Be Elevated in Prolonged Complete Remission. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 400-405.	1.4	16
95	Cross-sensitivity between taxanes in patients with breast cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 904-906.	1.2	16
96	Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 381-391.	0.7	16
97	Ocular side effects of checkpoint inhibitors. <i>Survey of Ophthalmology</i> , 2021, 66, 951-959.	1.7	16
98	Secondary Prophylactic G-CSF (Filgrastim) Administration in Chemotherapy of Stage I and II Hodgkin's Lymphoma with ABVD. <i>Leukemia and Lymphoma</i> , 2001, 41, 353-358.	0.6	15
99	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006, 8, 193-199.	1.2	15
100	The "El Álamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. <i>Clinical and Translational Oncology</i> , 2006, 8, 508-518.	1.2	15
101	Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2009, 11, 363-375.	1.2	15
102	A Monolayer Coagglutination Microplate Technique for Typing Red Blood Cells. <i>Vox Sanguinis</i> , 1997, 72, 26-30.	0.7	14
103	Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. <i>Cancer Biomarkers</i> , 2007, 3, 325-333.	0.8	14
104	High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: A confirmatory prospective study. <i>Cancer</i> , 2007, 110, 2178-2185.	2.0	14
105	Spanish Breast Cancer Research Group (GEICAM) population-based study on breast cancer outcomes: El Álamo project (1990-1997). <i>Journal of Clinical Oncology</i> , 2005, 23, 585-585.	0.8	14
106	Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2. <i>Journal of Clinical Oncology</i> , 2017, 35, 1020-1020.	0.8	14
107	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017, 8, 21472-21482.	0.8	14
108	Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation. <i>International Journal of Biological Markers</i> , 2004, 19, 221-228.	0.7	14

#	ARTICLE	IF	CITATIONS
109	Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. <i>Cancers</i> , 2020, 12, 1212.	1.7	13
110	Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006-03).. <i>Journal of Clinical Oncology</i> , 2010, 28, 500-500.	0.8	13
111	A Neural Network Based Model for Prognosis of Early Breast Cancer. <i>Applied Intelligence</i> , 2004, 20, 231-238.	3.3	12
112	Male Breast Cancer: Immunohistochemical Subtypes and Clinical Outcome Characterization. <i>Oncology</i> , 2012, 83, 228-233.	0.9	12
113	The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. <i>ESMO Open</i> , 2016, 1, e000004.	2.0	12
114	Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients. <i>European Journal of Cancer</i> , 2021, 144, 224-231.	1.3	12
115	Sequential Doxorubicin and Docetaxel as First-Line Treatment in Metastatic Breast Cancer: A GEICAM-9801 Phase II Study. <i>Breast Cancer Research and Treatment</i> , 2003, 77, 1-8.	1.1	11
116	Presentation of Hodgkin's Lymphoma With Ophelia Syndrome. <i>Journal of Clinical Oncology</i> , 2007, 25, 1802-1803.	0.8	11
117	Prognostic value of serum angiogenic activity in colorectal cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 120-128.	1.6	11
118	Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients. <i>Clinical and Translational Oncology</i> , 2014, 16, 548-554.	1.2	11
119	Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, 343-347.	1.1	11
120	Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 180.	3.7	11
121	Cancer-related fatigue stratification system based on patient-reported outcomes and objective outcomes: A cancer-related fatigue ambulatory index. <i>PLoS ONE</i> , 2019, 14, e0215662.	1.1	11
122	Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	11
123	Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers. <i>Cancer Research</i> , 2017, 77, CT045-CT045.	0.4	11
124	Mapping the spatial distribution of entanglement in optical lattices. <i>Physical Review A</i> , 2010, 82, .	1.0	10
125	Outcome of Small Invasive Breast Cancer with No Axillary Lymph Node Involvement. <i>Breast Journal</i> , 2011, 17, 32-38.	0.4	10
126	Identification of genetic variants associated with capecitabine-induced handâ€™foot syndrome through integration of patient and cell line genomic analyses. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 231-237.	0.7	10

#	ARTICLE	IF	CITATIONS
127	Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1286-1294.	0.6	10
128	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1548-1556.	1.2	10
129	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. <i>Frontiers in Oncology</i> , 2019, 9, 1178.	1.3	10
130	Inertial Sensors Embedded in Smartphones as a Tool for Fatigue Assessment Based on Acceleration in Survivors of Breast Cancer. <i>Physical Therapy</i> , 2020, 100, 447-456.	1.1	10
131	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , 2016, 16, 415-428.	0.8	10
132	“Out of blue” Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin. <i>Annals of Oncology</i> , 2008, 19, 2093-2094.	0.6	9
133	Energy System Assessment in Survivors of Breast Cancer. <i>Physical Therapy</i> , 2020, 100, 438-446.	1.1	9
134	Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1988, 24, 633-635.	0.9	8
135	Alternating chemotherapy for small-cell lung cancer. A twelve-week schedule of six drugs. <i>Annals of Oncology</i> , 1992, 3, 31-35.	0.6	8
136	Multimodal treatment of desmoid tumours: the significance of local control. <i>Clinical and Translational Oncology</i> , 2011, 13, 189-193.	1.2	8
137	Update on the diagnosis of cancer of unknown primary (CUP) origin. <i>Clinical and Translational Oncology</i> , 2011, 13, 434-441.	1.2	8
138	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 303.	1.3	8
139	Structural validity and reliability of the Spanish Central Sensitization Inventory in breast cancer survivors. <i>Pain Practice</i> , 2021, 21, 740-746.	0.9	8
140	Early Breast Cancer Prognosis Prediction and Rule Extraction Using a New Constructive Neural Network Algorithm. , 2007, , 1004-1011.		8
141	Functions and workload of medical oncologists in Spain. <i>Clinical and Translational Oncology</i> , 2012, 14, 423-429.	1.2	7
142	Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 418-424.	1.2	7
143	Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 596-596.	0.8	7
144	Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer: GEICAM 2006-03”A multicenter, randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 1015-1015.	0.8	7

#	ARTICLE	IF	CITATIONS
145	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 827625.	1.3	7
146	Treatment for Relapse in Stage I/II Hodgkin's Lymphoma After Initial Single-Modality Treatment. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 389-392.	1.4	6
147	Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 329-331.	1.2	6
148	Recomendación para la determinación de HER2 en cáncer de mama. Consenso nacional de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM). <i>Revista Española De Patología</i> , 2009, 42, 3-16.	0.6	6
149	Optimal adjuvant hormonal therapy in postmenopausal women with hormone-receptor-positive early breast cancer: have we answered the question?. <i>Clinical and Translational Oncology</i> , 2010, 12, 614-620.	1.2	6
150	SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HCGCUs). <i>Clinical and Translational Oncology</i> , 2013, 15, 20-25.	1.2	6
151	Central sensitization in breast cancer survivors. <i>Journal of Applied Biobehavioral Research</i> , 2018, 23, e12120.	2.0	6
152	Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 462-470.	2.3	6
153	Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECp): Relevance of HER2 and hormonal status (HR). <i>Journal of Clinical Oncology</i> , 2007, 25, 10598-10598.	0.8	6
154	Prognosis of Microinvasive Breast Carcinoma with Negative Axillary Nodes in Accordance with TNM Classification Criteria. <i>Breast Journal</i> , 2010, 16, 669-671.	0.4	5
155	Regional and seasonal influence in patients' toxicity to adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 273-278.	1.1	5
156	Targeted therapies in the treatment of germ cell tumors: The need for new approaches against chorion tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 444-451.	2.0	5
157	Time to Diagnosis of Ewing Tumors in Children and Adolescents Is Not Associated With Metastasis or Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 4020-4020.	0.8	5
158	Winding number order in the Haldane model with interactions. <i>New Journal of Physics</i> , 2016, 18, 033022.	1.2	5
159	Design and implementation of a standard care programme of therapeutic exercise and education for breast cancer survivors. <i>Supportive Care in Cancer</i> , 2022, 30, 1243-1251.	1.0	5
160	Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT.. <i>Journal of Clinical Oncology</i> , 2011, 29, 5528-5528.	0.8	5
161	First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1047-1047.	0.8	5
162	P198 Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancer. <i>Breast</i> , 2011, 20, S43.	0.9	4

#	ARTICLE	IF	CITATIONS
163	Proliferation Determined by ki67 Marker and pCR in Locally Advanced Breast Cancer Patients Treated with Neo-adjuvant Chemotherapy. <i>Breast Journal</i> , 2013, 19, 685-686.	0.4	4
164	Supervised discretization can discover risk groups in cancer survival analysis. <i>Computer Methods and Programs in Biomedicine</i> , 2016, 136, 11-19.	2.6	4
165	Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer. <i>Pathology and Oncology Research</i> , 2018, 24, 871-879.	0.9	4
166	Hereditary breast and ovarian cancer in Andalusian families: a genetic population study. <i>BMC Cancer</i> , 2018, 18, 647.	1.1	4
167	Cisplatin, 5-Fluorouracil, and High-Dose Folinic Acid in Patients with Advanced Unresectable Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 140-143.	0.6	4
168	Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2 ⁺ advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: A subgroup analysis of the MONALEESA-2 trial. , 2017, , .		4
169	Integrative cluster classification to predict pathological complete response to neoadjuvant chemotherapy in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 579-579.	0.8	4
170	Factors associated with upper limb function in breast cancer survivors. <i>PM and R</i> , 2023, 15, 151-156.	0.9	4
171	Current controversies in the management of early breast cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 375-84.	1.2	3
172	Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients. <i>Clinical and Translational Oncology</i> , 2009, 11, 727-736.	1.2	3
173	The relevance of the Spanish society for medical oncology (SEOM)â€™s clinical oncology guidelines. <i>Clinical and Translational Oncology</i> , 2010, 12, 707-708.	1.2	3
174	Abstract P2-10-11: Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2 ⁻ breast cancer patients: results from the GEICAM/9906 trial.. , 2012, , .		3
175	Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, 5594-5594.	0.8	3
176	Health-related quality of life of postmenopausal women with hormone receptor ⁺ positive, HER2-advanced breast cancer treated with ribociclib + letrozole: Results from MONALEESA-2.. <i>Journal of Clinical Oncology</i> , 2017, 35, 133-133.	0.8	3
177	Time-to-progression in breast cancer: A stratification model for clinical trials. <i>Breast</i> , 2008, 17, 239-244.	0.9	2
178	Current controversies in the management of breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 278-286.	1.2	2
179	Effectiveness of an individualized program of muscular strength and endurance with aerobic training for improving germ cell cancer-related fatigue in men undergoing chemotherapy: EFICATEST study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 8.	0.7	2
180	Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). , 2015, , .		2

#	ARTICLE	IF	CITATIONS
181	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 507-507.	0.8	2
182	Pharmacogenetic study in patients (pts) with metastatic breast (BC) and colorectal cancer (CRC) treated with Capecitabine (C). <i>Journal of Clinical Oncology</i> , 2005, 23, 2005-2005.	0.8	2
183	Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2010, 28, e15507-e15507.	0.8	2
184	Goblet Cell Carcinoid of the appendix: a 52 years old male with acute appendicitis. <i>Oncologia</i> , 2007, 30, .	0.0	2
185	Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 284.	1.4	2
186	Development of a functional assessment task in metastatic breast cancer patients: the 30-second lie-to-sit test. <i>Disability and Rehabilitation</i> , 0, , 1-8.	0.9	2
187	Weekly First-Line Chemotherapy of Metastatic Breast Cancer with Cyclophosphamide and Epirubicin. <i>Tumori</i> , 1992, 78, 338-340.	0.6	1
188	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. <i>Clinical and Translational Oncology</i> , 2008, 10, 552-559.	1.2	1
189	SEOM clinical guidelines: a necessary tool. <i>Clinical and Translational Oncology</i> , 2011, 13, 519-519.	1.2	1
190	Antiangiogenic therapy of breast cancer. How did we get here? The road not taken. <i>Clinical and Translational Oncology</i> , 2011, 13, 765-766.	1.2	1
191	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. <i>Clinical and Translational Oncology</i> , 2012, 14, 820-826.	1.2	1
192	Practical guidelines for dose individualization of anticancer targeted drugs. <i>Clinical and Translational Oncology</i> , 2012, 14, 812-819.	1.2	1
193	Advanced Online Survival Analysis Tool for Predictive Modelling in Clinical Data Science. <i>PLoS ONE</i> , 2016, 11, e0161135.	1.1	1
194	Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. <i>BMC Cancer</i> , 2016, 16, 829.	1.1	1
195	Grado de acuerdo entre la acelerometrÃa y el Cuestionario Internacional de Actividad FÃsica en pacientes supervivientes de cÃncer de mama. <i>Fisioterapia</i> , 2018, 40, 26-35.	0.2	1
196	Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma. <i>International Journal of Hematology</i> , 2021, , 1.	0.7	1
197	Abstract P3-07-15: Prosigna® subtype correlation is a strong predictor of response to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) study. , 2016, , .		1
198	Phase I study of high-dose bi-weekly gemcitabine at a constant rate infusion (CRI) without growth factor support in advanced solid tumors, including prior standard gemcitabine treated patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 2067-2067.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes.. Journal of Clinical Oncology, 2016, 34, 1585-1585.	0.8	1
200	Postchemotherapy resections of residual masses from metastatic nonseminomatous testicular germ cell tumors. A Spanish Germ Cell Group study. Journal of Clinical Oncology, 2005, 23, 4525-4525.	0.8	1
201	Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial.. Journal of Clinical Oncology, 2011, 29, 611-611.	0.8	1
202	Triple-negative breast cancer subtypes and pathologic complete-response rate to neoadjuvant chemotherapy: Results from the GEICAM/2006-2003 study.. Journal of Clinical Oncology, 2014, 32, 1024-1024.	0.8	1
203	Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patients. , 2016, , .		1
204	Outcomes of single versus double hormone receptor positive breast cancer.. Journal of Clinical Oncology, 2016, 34, 569-569.	0.8	1
205	BOMP/EPI intensive chemotherapy in poor-prognosis Germ Cell Tumors (GCT). European Journal of Cancer, 1997, 33, S39.	1.3	0
206	Looking for the right drug for the right patient: A tale of old drugs and new pathways. Clinical and Translational Oncology, 2005, 7, 373-376.	1.2	0
207	Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer. Breast Cancer Research, 2005, 7, 1.	2.2	0
208	An uncommon presentation of non-Hodgkin's lymphoma: Diffuse large-cell lymphoma presenting as a peritoneal mass. Leukemia and Lymphoma, 2006, 47, 933-934.	0.6	0
209	2017 POSTER Prognostic value and response to chemotherapy of immunohistochemical phenotypes (IP) of 141 operable breast cancer patients (pts) included in phase III trials of adjuvant therapy. European Journal of Cancer, Supplement, 2007, 5, 189.	2.2	0
210	Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: Overall Survival Versus Disease-Free Survival As a Primary End Point in Clinical Practice. Journal of Clinical Oncology, 2009, 27, e255-e256.	0.8	0
211	18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: The early metabolic response is the answer. European Journal of Cancer, 2013, 49, 3573-3574.	1.3	0
212	Bevacizumab in advanced breast cancer. Anti-Cancer Drugs, 2013, 24, 975-979.	0.7	0
213	Adjuvant high-dose interferon therapy for melanoma. Melanoma Research, 2014, 24, 522-523.	0.6	0
214	Locoregional Recurrence of Early Breast Cancer According to Intrinsic Subtype. International Journal of Radiation Oncology Biology Physics, 2014, 90, S272-S273.	0.4	0
215	PCN20 - CONTRIBUTION OF TRASTUZUMAB TO THE PROGNOSTIC IMPROVEMENT OF HER2-POSITIVE EARLY BREAST CANCER IN SPAIN. Value in Health, 2018, 21, S18.	0.1	0
216	Immunohistochemical (IHC) classification of DLBCL into CGB and non-CGB subtypes to predict survival after chemoimmunotherapy at the Virgen de la Victoria University Hospital. Annals of Oncology, 2018, 29, viii369.	0.6	0

#	ARTICLE	IF	CITATIONS
217	NOLUS: a predictive model to identify Basal-like and HER2-enriched intrinsic subtypes based on estrogen receptor (ER), progesterone receptor (PR) and Ki67 immunohistochemistry (IHC) in hormone receptor-positive/HER2-negative (HR+/HER2 ⁻) breast cancer (BC). <i>European Journal of Cancer</i> , 2018, 92, S138.	1.3	0
218	Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2019, 21, 534-538.	1.2	0
219	Adjuvant Chemotherapy in High-risk Stage I Non-seminomatous Germ Cell Tumours: the Spanish Germ Cell Cancer Group Experience. , 2002, , 242-242.		0
220	Sequential treatment with doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC). Final results of a Phase II GEICAM study. <i>European Journal of Cancer</i> , 2002, 38, S66.	1.3	0
221	Prognostic value of immunohistochemical phenotypes (IP) of 141 operable breast cancer patients (pts) included in phase III trials of adjuvant therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 21040-21040.	0.8	0
222	P3-05-04: Changes in Recurrence Risk of Breast Cancer Intrinsic Subtypes over Time.. , 2011, , .		0
223	P3-16-08: A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC.. , 2011, , .		0
224	Abstract P2-13-17: Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo I-III breast cancer registry (1990-2001).. , 2015, , .		0
225	Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 569-569.	0.8	0
226	Abstract P5-15-06: Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC).. , 2017, , .		0
227	Plasma sequencing of ctDNA in early stage breast cancer as part of the screening process.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12073-12073.	0.8	0
228	Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14).. <i>Journal of Clinical Oncology</i> , 2018, 36, 592-592.	0.8	0
229	Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval. <i>Oncotarget</i> , 2019, 10, 4321-4332.	0.8	0
230	Abstract P4-07-10: Patient profiles, management and treatment patterns in HR+, HER2- early breast cancer in a real-world setting in Spain. <i>Cancer Research</i> , 2022, 82, P4-07-10-P4-07-10.	0.4	0
231	Metastatic basal cell carcinoma and Turner syndrome: an unusual coincidence. <i>European Journal of Dermatology</i> , 2010, 20, 848-9.	0.3	0
232	Role of germline variants in the metastasis of breast carcinomas. <i>Oncotarget</i> , 2022, 13, 843-862.	0.8	0